Becton, Dickinson and Company
) rose following the company's announcement of developing and
launching the Odon Device, an obstetrical instrument helpful in
mitigating the complications from obstructed labor during
childbirth. The company will collaborate with World Health
Organization (WHO) and Saving Lives at Birth: A Grand Challenge
for Development for the device.
ALPHATEC HLDGS (ATEC): Free Stock Analysis
BECTON DICKINSO (BDX): Free Stock Analysis
CARDINAL HEALTH (CAH): Free Stock Analysis
STRAUMANN (SAUHF): Get Free Report
To read this article on Zacks.com click here.
Saving Lives at Birth has been initiated by the U.S. Agency for
International Development (USAID), the Government of Norway, the
Bill & Melinda Gates Foundation, Grand Challenges Canada, and
the U.K. Department for International Development (DFID). Since
its launch in Mar 9, 2011, the program has been seeking to find
innovative solutions for preventing maternal and neonatal deaths,
and stillbirth in developing countries especially in sub-Saharan
Africa and South Asia as well as for treatment approaches for
pregnant women and newborns at the time of delivery.
It has been estimated that roughly 10 million women face
pregnancy-related complications, and 260,000 maternal deaths
occurred in 2012 due to these complications. About 90% of these
mortalities occur in developing countries. It is seen that about
3 million newborn babies die each year while 2.6 million are
stillborn due to obstructed labor problems.
The Odon Device, named after its Argentinean inventor Jorge Odon,
provides gentle delivery of newborns through the birth canal
during complicated second-stage labor. Other devices that serve
the same purpose include forceps, vacuum and C-sections. Forceps
and vacuum are prone to cause damage to mothers and newborns
while C-sections are less accessible in developing countries.
The Odon Device has been endorsed by WHO in the Saving Lives at
Birth competition. WHO will also lead implementation of clinical
studies for the device. The first phase of a clinical study was
completed in Argentina in 2012.
Becton, Dickinson and Company will develop the device at its
technology center in Singapore. The company intends to bring the
device with high-scale and low-cost production at affordable
prices in developing countries.
Currently, BDX carries a Zacks Rank #3 (Hold). Other medical
stocks that are worth considering include
Cardinal Health, Inc.
STRAUMANN HLD N AKT
), both with a Zacks Rank #1 (Strong Buy), and
Alphatec Holdings, Inc.
) with a Zacks Rank #2 (Buy).